1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
HOB Biotech Group Corp.,Ltd

HOB Biotech Group Corp.,Ltd

688656.SS
HOB Biotech Group Corp.,LtdCN flagShanghai Stock Exchange
100.47
CNY
-3.68
- -
6.38BMarket Cap
HOB Biotech Group Corp.,Ltd
688656.SS
(Shanghai Stock Exchange)

Recent

price

100.47

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
3.22
4.41
5.48
4.7
5.16
5.08
6.25
6.45
6.35
7.12
Revenue per Share
- -
0.47
0.88
1.35
1.2
1.4
0.66
0.75
0.59
0.37
0.53
Basic EPS, GAAP
- -
0.03
0.44
0.71
0.03
-1.02
-2.57
-1.19
-0.87
-0.02
-1.89
Free Cash Flow per Basic Share
- -
0.04
0.04
0.88
1.04
0.32
0.55
0.33
0.45
0.33
0.41
Dividend per Share
- -
1.35
1.32
1.49
2.55
3.16
3.12
3.57
3.8
3.86
4.23
Book Value per Share
- -
1.73
2.91
2.92
4.13
12.31
12.15
12.66
12.86
12.9
14.7
Tangible Book Value per Share
- -
45
46
47
47
62
63
63
62
63
55
Basic Weighted Avg Shares
112
146
201
259
222
318
320
394
402
398
389
Sales/Revenue/Turnover
4.19
22.67
29.25
27.32
23.49
27.2
13.34
13.99
11.35
5
8.54
Operating Margin (%)
5
7
10
13
15
25
33
40
45
65
- -
Depreciation Expense
4
21
40
64
57
86
42
47
37
23
29
Net Income, GAAP
- -
13.99
14.04
13.21
13.04
13.05
10.39
16.41
10.31
6.53
4.31
Effective Tax Rate (%)
3.88
14.59
19.93
24.64
25.52
27.13
13
12
9.15
5.82
7.45
Profit Margin (%)
-2
16
63
51
95
484
270
192
82
127
97
Working Capital
8
7
6
5
32
5
10
1
10
1
17
LT Debt
57
79
133
150
206
770
779
811
812
820
814
Total Equity
- -
26.7
37.27
34.52
19.62
14.1
4.63
5.36
4.53
2.06
3.48
Return on Invested Capital (%)
- -
27.61
46.85
65.15
39.8
43.9
17.8
18.2
12.34
7.83
9.64
Return on Capital (%)
- -
46.48
66.16
97.93
59.44
54.81
21.3
22.43
15.92
9.68
12.85
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
108
107
88
LT Borrowings
8
16
16
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
63
63
Market Capitalization
6,064
4,747
7,420

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
292
263
243
Cash, Cash Equivalents & STI
122
94
67
Accounts Receivable, Net
49
41
54
Inventories
111
115
110
Total Current Liabilities
210
169
146
Payables & Accruals
- -
- -
- -
ST Debt
108
107
88
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
55.93%
0.97%
Free Cash Flow
- -
-1,065.23%
-98.22%
Net Income, GAAP
- -
-9%
-36.96%
Sales/Revenue/Turnover
- -
13.63%
-0.98%
Total Cash Common Dividend
- -
-3.08%
-26.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
86
117
104
95
402
2025
78
112
106
- -
398
2026
79
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
0.59
2025
0.03
- -
- -
- -
0.37
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.45
2025
0.02
- -
- -
- -
0.33
2026
- -
- -
- -
- -
- -
Similar Companies
Visioneering Technologies, Inc. (VTI.AX)
Nexalin Technology, Inc. (NXLIW)
enVVeno Medical Corporation (NVNOW)
Micron Solutions, Inc. (MICR)
Avita Medical Inc. (RCEL)
CONMED Corporation (CNMD)
Business
HOB Biotech Group Corp Ltd (688656.SS) operates as an innovative in vitro diagnostic company focused on the research, development, production and sales of diagnostic reagents and instruments for allergy and autoimmune diseases. The company provides a range of diagnostic tools including line immunoassays under the BioLINE brand offering 18 panels covering 76 food and inhalant allergens; enzyme-linked immunosorbent assays under the BioLISA brand; and advanced chemiluminescent paramagnetic microparticle immunoassays under the BioCLIA brand detecting 76 single allergens and 10 mix allergens, serving laboratories and hospitals in China across 34 provinces and internationally. Founded in 2009 and headquartered in Suzhou, China, HOB Biotech maintains world-class R&D centers in Suzhou and California, US, alongside an ISO 13485-certified manufacturing facility in Suzhou, positioning it as China's market leader in allergy diagnostics and a rising star in autoimmune diagnostics with over 100 product registration certificates and dozens of patents.